Phase 2 Trial of Nintedanib DPI in Idiopathic Pulmonary Fibrosis Initiated by Mannkind Corporation
Mannkind Corporation is conducting Phase 2 trial of inhaled Nintedanib DPI in patients with IPF, focusing on safety and preliminary efficacy.
Asset / Drug
Drug and asset intelligence for Nintedanib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.